{"id":"https://openalex.org/W4401280614","doi":null,"title":"Spevigo\u00ae (Spesolimab-Sbzo) Injection for the Treatment of Generalized Pustular Psoriasis.","display_name":"Spevigo\u00ae (Spesolimab-Sbzo) Injection for the Treatment of Generalized Pustular Psoriasis.","publication_year":2024,"publication_date":"2024-01-01","ids":{"openalex":"https://openalex.org/W4401280614","pmid":"https://pubmed.ncbi.nlm.nih.gov/39089999"},"language":"en","primary_location":{"id":"pmid:39089999","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39089999","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Skinmed","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100603158","display_name":"Aditya Kumar Gupta","orcid":"https://orcid.org/0000-0002-8664-7723","observed_orcids":["https://orcid.org/0000-0002-8664-7723"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I4210126549","display_name":"Mediprobe Research (Canada)","ror":"https://ror.org/02x3bf117","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210126549"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Aditya K Gupta","raw_affiliation_strings":["Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada","Mediprobe Research Inc., London, Ontario, Canada; agupta@mediproberesearch.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada","institution_ids":["https://openalex.org/I185261750"]},{"raw_affiliation_string":"Mediprobe Research Inc., London, Ontario, Canada; agupta@mediproberesearch.com","institution_ids":["https://openalex.org/I4210126549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073064001","display_name":"Avantika Mann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126549","display_name":"Mediprobe Research (Canada)","ror":"https://ror.org/02x3bf117","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210126549"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Avantika Mann","raw_affiliation_strings":["Mediprobe Research Inc., London, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mediprobe Research Inc., London, Ontario, Canada","institution_ids":["https://openalex.org/I4210126549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077394930","display_name":"Kimberly Dawn Vincent","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimberly Vincent","raw_affiliation_strings":["Private Practice Sevierville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Private Practice Sevierville, TN","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033724363","display_name":"William Abramovits","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123534392","display_name":"University of North Texas","ror":"https://ror.org/00v97ad02","country_code":"US","type":"education","lineage":["https://openalex.org/I123534392"]},{"id":"https://openalex.org/I4210160418","display_name":"Baylor Scott & White Health","ror":"https://ror.org/05wevan27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160418"]},{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Abramovits","raw_affiliation_strings":["Department of Dermatology, University of Texas at Southwestern Medical School, Dallas, TX","Baylor Scott & White University Hospital, Dallas, TX","The University of North Texas Dermatology Residency Program, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University of Texas at Southwestern Medical School, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]},{"raw_affiliation_string":"Baylor Scott & White University Hospital, Dallas, TX","institution_ids":["https://openalex.org/I4210160418"]},{"raw_affiliation_string":"The University of North Texas Dermatology Residency Program, Dallas, TX","institution_ids":["https://openalex.org/I123534392"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.10341821,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"2","first_page":"134","last_page":"137"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/spesolimab","display_name":"spesolimab","score":0.8799999952316284},{"id":"https://openalex.org/keywords/generalized-pustular-psoriasis","display_name":"generalized pustular psoriasis","score":0.9169999957084656},{"id":"https://openalex.org/keywords/interleukin-36-receptor-antagonist","display_name":"IL36RN","score":0.8370000123977661},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8949999809265137},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5950000286102295},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.5210000276565552}],"concepts":[{"id":"https://openalex.org/C2776907424","wikidata":"https://www.wikidata.org/wiki/Q5532501","display_name":"Generalized pustular psoriasis","level":3,"score":0.8512784242630005},{"id":"https://openalex.org/C2779911711","wikidata":"https://www.wikidata.org/wiki/Q30314007","display_name":"Pustular psoriasis","level":3,"score":0.6990532279014587},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.6639013290405273},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6391318440437317},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6025867462158203}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:39089999","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39089999","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Skinmed","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4400891017","https://openalex.org/W4389265660","https://openalex.org/W4200421636","https://openalex.org/W4408244574","https://openalex.org/W4360604460","https://openalex.org/W4397014478","https://openalex.org/W4317646813","https://openalex.org/W4322765827","https://openalex.org/W4368355825","https://openalex.org/W4409566833"],"abstract_inverted_index":{"(spesolimab-sbzo)":[0],"injection":[1],"was":[2,86,106,129,153],"recently":[3],"approved":[4],"for":[5],"the":[6,25,69,102,107,121,137,146,161,170,174,190,197],"treatment":[7],"of":[8,71,76,96,111,123,134,143,158,167,187],"generalized":[9],"pustular":[10],"psoriasis":[11],"(GPP)":[12],"in":[13,136,145,160,169,184,189,196],"adults":[14],"aged":[15],"18-":[16],"75":[17],"years.":[18],"Spesolimab,":[19],"a":[20,45,72],"monoclonal":[21],"antibody,":[22],"binds":[23],"to":[24,37,57,67,180],"interleukin-36":[26],"(IL-36)":[27],"receptor":[28],"and":[29,42,62,101,140,164,193],"prevents":[30],"its":[31],"activation":[32],"by":[33,131,155],"IL-36":[34],"cytokines,":[35],"leading":[36],"reduced":[38],"inflammation,":[39],"skin":[40],"lesions,":[41],"flares.":[43,82],"In":[44,173],"randomized":[46,56],"placebo-controlled,":[47],"phase":[48],"2":[49],"study":[50],"(Effisayil-1,":[51],"NCT03782792),":[52],"53":[53],"patients":[54,135,144,159,168,188],"were":[55,182],"spesolimab":[58,77,138,162,191],"(n":[59,64],"=":[60,65],"35)":[61],"placebo":[63,79,147,171,198],"18)":[66],"evaluate":[68],"effect":[70],"one-time":[73],"900-mg":[74],"dose":[75],"versus":[78],"against":[80],"GPP":[81],"The":[83,126,149],"primary":[84,127],"endpoint":[85,105,128,152],"Generalized":[87],"Pustular":[88],"Psoriasis":[89],"Physician":[90],"Global":[91],"Assessment":[92],"(GPPGA)":[93],"pustulation":[94],"subscore":[95],"0":[97,112],"(no":[98],"visible":[99],"pustules)":[100],"key":[103,150],"secondary":[104,151],"GPPGA":[108],"total":[109],"score":[110],"or":[113,116],"1":[114],"(clear":[115],"almost":[117],"clear":[118],"skin)":[119],"at":[120],"end":[122],"week":[124],"1.":[125],"achieved":[130,154],"54%":[132],"(19/35)":[133],"group":[139,163,192],"6%":[141],"(1/18)":[142],"group.":[148,172,199],"43%":[156],"(15/35)":[157],"11%":[165],"(2/18)":[166],"first":[175],"week,":[176],"adverse":[177],"events":[178],"(mild":[179],"severe)":[181],"reported":[183],"66%":[185],"(22/35)":[186],"56%":[194],"(10/18)":[195]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-08-03T00:00:00"}